Allergan gets US nod for Inamed merger:
This article was originally published in Clinica
Allergan has cleared its final regulatory hurdle to closing its acquisition of Inamed, following yesterday's green light from the US Federal Trade Commission. Irvine California-based Allergan now expects to complete its exchange offer for outstanding shares of the breast implant maker by Friday (March 10) and to close the deal immediately after. Allergan agreed to buy the fellow Californian company in December last year for $84 per share in cash or 0.8498 of Allergan stock.